CSPC Pharmaceutical Group (CSPC Pharmaceutical Group) COGS-to-Revenue : 0.29 (As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is CSPC Pharmaceutical Group COGS-to-Revenue?

CSPC Pharmaceutical Group's Cost of Goods Sold for the three months ended in Dec. 2023 was $308 Mil. Its Revenue for the three months ended in Dec. 2023 was $1,062 Mil.

CSPC Pharmaceutical Group's COGS to Revenue for the three months ended in Dec. 2023 was 0.29.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. CSPC Pharmaceutical Group's Gross Margin % for the three months ended in Dec. 2023 was 70.99%.

CSPC Pharmaceutical Group COGS-to-Revenue Historical Data

The historical data trend for CSPC Pharmaceutical Group's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CSPC Pharmaceutical Group COGS-to-Revenue Chart

CSPC Pharmaceutical Group Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

COGS-to-Revenue

Get a 7-Day Free Trial

0.28

0.25

0.24

0.28

0.29

CSPC Pharmaceutical Group Quarterly Data
	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
COGS-to-Revenue	Get a 7-Day Free Trial															0.30	0.31	0.29	0.29	0.29

CSPC Pharmaceutical Group COGS-to-Revenue Calculation

CSPC Pharmaceutical Group's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	1298.763	/	4404.654
	=	0.29

CSPC Pharmaceutical Group's COGS to Revenue for the quarter that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	308.177	/	1062.3
	=	0.29

CSPC Pharmaceutical Group (OTCPK:CHJTF) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

CSPC Pharmaceutical Group's Gross Margin % for the three months ended in Dec. 2023 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	308.177 / 1062.3
	=	70.99 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

CSPC Pharmaceutical Group COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of CSPC Pharmaceutical Group's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

CSPC Pharmaceutical Group (CSPC Pharmaceutical Group) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » CSPC Pharmaceutical Group Ltd (OTCPK:CHJTF) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

CSPCY:USA 01093:Hong Kong CVG:Germany

Address

No. 226 Huanghe Street, Hebei Province, Shijiazhuang, CHN, 050035

Website

https://www.cspc.com.hk

CSPC Pharmaceutical Group listed on the Hong Kong Stock Exchange in 1994 and is one of the largest pharmaceutical companies in China. Its biggest business segment is the finished drugs segment which accounts for nearly 80% of its total revenue. Now it has a diversified pipeline portfolio in seven therapeutic areas including nervous system diseases, oncology, anti-infective to cardiovascular disease, respiratory system disease, and metabolism. CSPC also has a bulk drug product segment including vitamin C, antibiotics, and a caffeine series.

CSPC Pharmaceutical Group (CSPC Pharmaceutical Group) Headlines

From GuruFocus

Value Partners Classic Fund Comments on CSPC Pharmaceutical

By Vera Yuan Vera Yuan • 07-29-2014